Jiangsu GDK Financials
| 688670 Stock | 11.55 0.65 5.33% |
Jiangsu | Select Account or Indicator |
Understanding current and past Jiangsu GDK Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Jiangsu GDK's financial statements are interrelated, with each one affecting the others. For example, an increase in Jiangsu GDK's assets may result in an increase in income on the income statement.
Please note, the presentation of Jiangsu GDK's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Jiangsu GDK's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Jiangsu GDK's management manipulating its earnings.
Jiangsu GDK Stock Summary
Jiangsu GDK competes with Zhongyin Babi, Jiamei Food, New Hope, V V, and Beingmate Baby. Jiangsu GDK is entity of China. It is traded as Stock on SHG exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | China Stock View All |
| Exchange | Shanghai Stock Exchange |
| ISIN | CNE100004NR4 |
| Business Address | 12 Yujin Road, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.gdkbio.com |
| Phone | 86 523 8620 0906 |
You should never invest in Jiangsu GDK without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Jiangsu Stock, because this is throwing your money away. Analyzing the key information contained in Jiangsu GDK's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Jiangsu GDK Key Financial Ratios
Jiangsu GDK's financial ratios allow both analysts and investors to convert raw data from Jiangsu GDK's financial statements into concise, actionable information that can be used to evaluate the performance of Jiangsu GDK over time and compare it to other companies across industries.| Revenue | 134.59 M | ||||
| Gross Profit | 80.8 M | ||||
| EBITDA | (85.03 M) | ||||
| Net Income | (70.99 M) | ||||
| Total Asset | 1.63 B |
Jiangsu GDK Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 778.0M | 1.8B | 1.8B | 1.6B | 1.9B | 1.1B | |
| Other Current Liab | 405.6M | 187.2M | 153.2M | 161.5M | 145.4M | 199.2M | |
| Net Debt | 49.4M | 208.7M | (26.7M) | (132.7M) | (119.4M) | (113.4M) | |
| Retained Earnings | 126.2M | 200.4M | 193.8M | 105.2M | 121.0M | 127.1M | |
| Accounts Payable | 25.1M | 58.5M | 98.9M | 86.7M | 99.7M | 58.1M | |
| Cash | 88.0M | 36.7M | 174.7M | 70.4M | 81.0M | 59.9M | |
| Inventory | 33.3M | 28.0M | 32.0M | 22.0M | 25.3M | 21.6M | |
| Total Liab | 535.5M | 293.1M | 367.1M | 260.5M | 234.5M | 311.1M | |
| Total Current Assets | 522.8M | 1.1B | 951.0M | 722.2M | 830.6M | 532.3M | |
| Short Term Debt | 56.9M | 296.7M | 10.0M | 42.0M | 48.3M | 85.4M | |
| Intangible Assets | 49.5M | 57.9M | 66.6M | 77.5M | 89.1M | 58.5M | |
| Net Receivables | 355.0M | 342.8M | 341.1M | 81.2M | 93.4M | 88.7M | |
| Net Invested Capital | 539.3M | 1.5B | 1.5B | 1.4B | 1.7B | 1.1B | |
| Short Long Term Debt | 296.7M | 10.0M | 42.0M | 64.1M | 57.7M | 75.2M | |
| Net Working Capital | 13.7M | 848.0M | 648.5M | 494.9M | 569.1M | 354.6M |
Jiangsu GDK Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 9.6M | 9.9M | 1.3M | 1.9M | 2.2M | 2.1M | |
| Operating Income | 211.7M | 150.8M | 95.2M | (40.7M) | (46.8M) | (44.5M) | |
| Ebit | (25.1M) | 211.7M | 150.8M | 95.2M | 109.4M | 64.1M | |
| Research Development | 28.5M | 35.3M | 32.4M | 15.5M | 17.8M | 26.1M | |
| Ebitda | (1.8M) | 263.1M | 178.9M | 124.9M | 143.7M | 95.7M | |
| Income Before Tax | 210.9M | 84.0M | 48.4M | (86.6M) | (99.6M) | (94.6M) | |
| Net Income | 155.0M | 82.5M | 41.5M | (71.0M) | (81.6M) | (77.6M) | |
| Income Tax Expense | (12.2M) | 55.9M | 1.5M | 6.9M | 7.9M | 4.4M | |
| Tax Provision | 55.9M | 1.5M | 6.9M | (15.6M) | (14.0M) | (13.3M) | |
| Net Interest Income | (9.4M) | (7.1M) | 353.2K | (43.0K) | (49.4K) | (51.9K) | |
| Interest Income | 266.0K | 2.7M | 1.7M | 1.9M | 2.2M | 1.4M | |
| Total Revenue | 589.1M | 392.3M | 318.5M | 134.6M | 121.1M | 240.3M | |
| Gross Profit | 515.4M | 335.1M | 267.9M | 104.7M | 94.3M | 89.5M | |
| Cost Of Revenue | 73.7M | 57.2M | 50.6M | 29.9M | 34.3M | 48.8M |
Jiangsu GDK Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Jiangsu GDK Biotechnology. It measures of how well Jiangsu is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Jiangsu GDK brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Jiangsu had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Jiangsu GDK has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (14.8M) | (48.9M) | (39.0M) | (44.8M) | (40.4M) | (38.3M) | |
| Change In Cash | 80.5M | (51.3M) | 138.0M | (104.3M) | (93.9M) | (89.2M) | |
| Free Cash Flow | 68.6M | (282.5M) | (129.6M) | 26.9M | 24.2M | 25.4M | |
| Change In Working Capital | (112.3M) | (70.3M) | (61.3M) | 87.2M | 100.3M | 105.3M | |
| Begin Period Cash Flow | 7.6M | 88.0M | 36.7M | 174.7M | 200.9M | 211.0M | |
| Other Cashflows From Financing Activities | 139M | 185.2M | 1.4B | 52M | 59.8M | 56.8M | |
| Depreciation | 25.8M | 28.1M | 29.8M | 29.9M | 34.4M | 27.7M | |
| Other Non Cash Items | 40.9M | 63.7M | 28.6M | 3.3M | 3.8M | 3.6M | |
| Dividends Paid | 8.4M | 9.9M | 45.3M | 19.5M | 22.4M | 14.6M | |
| Capital Expenditures | 40.8M | 386.4M | 168.2M | 54.0M | 62.1M | 111.7M | |
| Total Cash From Operating Activities | 109.5M | 103.9M | 38.6M | 80.9M | 93.0M | 97.7M | |
| Net Income | 155.0M | 82.5M | 41.5M | (71.0M) | (81.6M) | (77.6M) | |
| Total Cash From Financing Activities | 82.3M | 42.3M | 841.1M | (13.3M) | (15.2M) | (14.5M) | |
| End Period Cash Flow | 88.0M | 36.7M | 174.7M | 70.4M | 81.0M | 59.9M | |
| Investments | (71.3M) | (996.4M) | 112.7M | (187.7M) | (168.9M) | (177.4M) |
Jiangsu Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Jiangsu GDK's current stock value. Our valuation model uses many indicators to compare Jiangsu GDK value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Jiangsu GDK competition to find correlations between indicators driving Jiangsu GDK's intrinsic value. More Info.Jiangsu GDK Biotechnology is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Jiangsu GDK by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Jiangsu GDK's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Jiangsu GDK Biotechnology Systematic Risk
Jiangsu GDK's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Jiangsu GDK volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Jiangsu GDK Biotechnology correlated with the market. If Beta is less than 0 Jiangsu GDK generally moves in the opposite direction as compared to the market. If Jiangsu GDK Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Jiangsu GDK Biotechnology is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Jiangsu GDK is generally in the same direction as the market. If Beta > 1 Jiangsu GDK moves generally in the same direction as, but more than the movement of the benchmark.
Jiangsu GDK Biotechnology Total Assets Over Time
Jiangsu GDK Thematic Clasifications
Jiangsu GDK Biotechnology is part of Biotech investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services
This theme covers Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services. Get More Thematic Ideas
| Biotech | View |
Jiangsu GDK March 24, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Jiangsu GDK help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Jiangsu GDK Biotechnology. We use our internally-developed statistical techniques to arrive at the intrinsic value of Jiangsu GDK Biotechnology based on widely used predictive technical indicators. In general, we focus on analyzing Jiangsu Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Jiangsu GDK's daily price indicators and compare them against related drivers.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 11.84 | |||
| Value At Risk | (4.39) | |||
| Potential Upside | 3.35 |
Complementary Tools for Jiangsu Stock analysis
When running Jiangsu GDK's price analysis, check to measure Jiangsu GDK's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jiangsu GDK is operating at the current time. Most of Jiangsu GDK's value examination focuses on studying past and present price action to predict the probability of Jiangsu GDK's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jiangsu GDK's price. Additionally, you may evaluate how the addition of Jiangsu GDK to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |